The Evaluation Value of CT in the Efficacy of Neoadjuvant Chemotherapy in Ovarian Cancer Patients

Abstract

Aim. To discuss the evaluation value of CT in the efficacy of neoadjuvant chemotherapy in patients with ovarian cancer. Methods. The clinical, pathological, and CT imaging information of 72 patients with ovarian cancer treated in our hospital from January 2018 to January 2022 were retrospectively analyzed. CT examination and pathological examination were compared to evaluate the efficacy of neoadjuvant chemotherapy. Results. Using the CRS grading system, 26 cases (36.11%) scored 1, 42 cases (58.33%) scored 2, and 4 cases (5.56%) scored 3. CRS grading system scores of 1, 2, 3, and 4–7 patients were compared, $P$  > 0.05. The CT manifestations of lymphadenectasis, degree of peritoneal thickening, ascites, and maximum length diameter of the mass were compared between the patients before and after chemotherapy, $P$  < 0.05. According to RECIST 1.1, there were 1 (1.39%) CR, 38 (52.78%) PR, 29 (40.28%) SD, and 4 (5.56%) PD. The comparison was done between RECIST 1.1 and CRS grading system, $P$  > 0.05. Conclusion. CT could be used to evaluate the efficacy of neoadjuvant chemotherapy for ovarian cancer.